AMA Expresses Concern Over New Federal Peptide Compounding Policy

The American Medical Association (AMA) has issued a warning regarding a new federal policy that permits the compounding of non-FDA-approved substances, specifically peptides. AMA President Willie Underwood III stated this policy increases the risk of serious patient harm, emphasizing the need for scientific evidence to ensure medical product safety. This raises concerns about patient safety and the regulation of compounded substances.